Maintaining strong profitability, net income affected by FX
Net profit amounted to €170.1m; -28% yoy
Sales increased in all sales regions and in majority of sales markets
Strong sales increase in Vet. (+23%), Spa. (+18%), OTC (+6%), and Rx (+6%)
RUB volatility affecting operating and net financial result → - €29.4m net financial result
5 new MA in H1; R&D: 9.3 % of revenue; CAPEX: €45.6m
SALES 5Y CAGR: 6.2%
920
In
759 802
807
857
EUR
million
1-6 19 1-6 20 1-6 21 1-6 22 1-6 23
EBIT 5Y CAGR: 11.8%
In
236
217
201
217
EUR
155
million
1-6 19 1-6 20 1-6 21 1-6 22* 1-6 23
*1-6 2022 EBIT is adjusted figure
✓ Challenging environment in region East Europe continues
Remaining firmly on track with core strategic objectives
of vertical integration →
✓ 2023 guidance: sales €1,755m, net income ≈ €300m
strengthening the vital elements of value creation chain
www.krka.biz
2
Well-Diversified Activities
Providing access to high quality affordable medicines
Krka's presence on 70+ markets in 6 sales regions
49 subsidiaries outside Slovenia:
45% of all Krka Group workforce
Sales regions
Region Slovenia
Region Central Europe
Region East Europe
Region South-East Europe
Region West Europe
Region Overseas markets
Manufacturing locations
Slovenia I Russian Federation
Poland I Germany I Croatia I China
55+ million patients daily use Krka's
medicines worldwide
17 bn FDF produced annually in various
therapeutic groups
Operating in many low to middle income countries, creating savings for patients & healthcare systems
www.krka.biz
3
Long-term Stable Operating Business Growth
Revenue rising along with manufacturing output
THE BIG 5
Pieces sold CAGR (2005-2022)
6.9%
over 1b in
Sales revenue CAGR (2005-2022) 7.4%
sales volume
Global pharma market CAGR (2005-2022) 5.6%
18
Net income CAGR (2005-2022)
10.0%
1,600
Manufacturing output growth (2005-2022) +185%
16
1,400
14
1,200
12
EURmillion
400
soldPiecesbillion
4
1,000
10
800
8
600
6
200
2
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
www.krka.biz
Sales revenue
Net profit
Pieces sold (billion)
4
Krka Group Sales by Regions
Continuation of good sales dynamics
H1 2023 sales: EUR 916.5 million of goods
and services; (+7% yoy; EUR +63.0m)
Largest market: Russian Federation Sales: EUR 180m; +4% yoy
167 180 168 173 180
In
EUR million
H1 19
H1 20
H1 21
H1 22
H1 23
Central Europe
❖ 2nd market Poland; Sales: EUR 93m; +5% yoy
EUR 212.9.m
+9%
88
89
93
East Europe
23.2%
(EUR +16.8m)
80
86
EUR 300.5m
+4% 32.8%
(EUR +12.8m)
H1 19
H1 20
H1 21
H1 22
H1 23
❖ 33d market Germany; Sales: EUR 49m; +4% yoy
19.8%
41
48
43
47
49
West Europe
South-East Europe
13.9%
4.1%
EUR 181.4m
+8%
EUR 127.4m
(EUR +12.8m)
H1 19
H1 20
H1 21
H1 22
H1 23
(EUR +8.2m)
+7%
6.2%
❖ 4th market Ukraine; Sales: EUR 39m; -16% yoy
Slovenia
Overseas Markets
36
37
46
46
39
EUR 56.6m
+15%
EUR 37.6m
+16%
(EUR +7.2m)
(EUR +5.2m)
H1 19
H1 20
H1 21
H1 22
H1 23
www.krka.biz
5 Nominal and relative change compared to same period year-over-year
In
EUR million
In
EUR million
In
EUR million
Attachments
Original Link
Original Document
Permalink
Disclaimer
KRKA dd published this content on 21 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 July 2023 06:47:10 UTC.
Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.
KRKA, D. D. 
